Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.010
-0.050 (-4.72%)
Feb 12, 2026, 4:00 PM EST - Market closed
Cardiol Therapeutics Employees
Cardiol Therapeutics had 18 employees as of December 31, 2024. The number of employees increased by 12 or 200.00% compared to the previous year.
Employees
18
Change
12
Growth
200.00%
Revenue / Employee
n/a
Profits / Employee
-$1,387,388
Market Cap
118.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 18 | - | - |
| Dec 31, 2018 | 6 | - | - |
| Sep 30, 2018 | 8 | - | - |
| Jun 30, 2018 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Organigram Global | 1,139 |
| Aurora Cannabis | 1,073 |
| InterCure | 320 |
| Anika Therapeutics | 288 |
| Alpha Teknova | 173 |
| Cumberland Pharmaceuticals | 91 |
| Assertio Holdings | 58 |
| Journey Medical | 41 |
CRDL News
- 2 days ago - Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure - Newsfile Corp
- 20 days ago - Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million - Newsfile Corp
- 27 days ago - Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Newsfile Corp
- 27 days ago - Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Newsfile Corp
- 4 weeks ago - Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile Corp
- 2 months ago - New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions - Newsfile Corp
- 3 months ago - Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 - Newsfile Corp
- 3 months ago - Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases - Newsfile Corp